Home Tags Gemtuzumab ozogamicin

Tag: gemtuzumab ozogamicin

Anti-CLL-1 ADC May Offer Effective and Safe Treatment Options for Patients...

Over the last 40 years treatment of acute myeloid leukemia or AML has not significantly changed.Today, the standard of care for AML is treatment...

Gemtuzumab Ozogamicin Granted Positive Opinion for Treatment of Previously Untreated, De...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology...

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

FDA Approval for Gemtuzumab Ozogamicin: Reintroduction Based on Favorable Risk:Benefit Profile

The U.S. Food and Drug Administration (FDA) has approved gemtuzumab ozogamicin (Mylotarg™, previously known as CMA-676; Wyeth Pharmaceuticals, a subsidiary of Pfizer) for the...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

What to Expect at PEGS Boston 2017: A New Pathway of...

From the Charlestown Navy Yard to the Paul Revere House, the Old State House on Washington Street, the New England Aquarium at Central Wharf...

Novel Cancer Therapeutics Drive Therapy Market

An increased need for better cancer treatment continues to boost the global cancer biological therapy market. According to a report published by Global Market...

Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators

In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....
Drugs & Durg Hunters

Drugs and Drug Hunters

All products of the creative process are a reflection of the individual makeup of the inventors.  A painting by Mark Rothko looks like a...

Study Links Gemtuzumab Ozogamicin Response in Pediatric AML to Expression Level...

Expression CD33 is largely restricted to hematopoietic cells. Because CD33 is consistently expressed on acute myeloid leukemia or AML blasts, it makes a promising...

FEATURED RESOURCES